research Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
Search
for
Sort by
Research
30-60 / 1000+ resultsresearch Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
research Scalp cooling to prevent chemotherapy-induced alopecia
Scalp cooling is an effective way to prevent hair loss from chemotherapy.
research Resistance Exercise and Art Therapy on Body Image in Breast Cancer: A Scoping Review
Resistance exercise improves body image in breast cancer survivors.
research Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial
Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.
research A Systematic Review of 207 Studies Describing Validation Aspects of the Dermatology Life Quality Index
The Dermatology Life Quality Index is reliable and consistent but needs more diverse participant studies.
research A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib
Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.
research Improving Quality of Life During Chemotherapy: Cannabinoids, Cryotherapy, and Scalp Cooling
Cannabis, cryotherapy, and scalp cooling can help improve the quality of life for chemotherapy patients.
research Hair safe study: Effects of scalp cooling on hair preservation and hair regrowth in breast cancer patients receiving chemotherapy - A prospective interventional study
Scalp cooling reduces hair loss during chemotherapy but doesn't help hair regrow after.
research The Economic Burden of Alopecia Areata in Romania
Alopecia areata in Romania has a high economic burden, with significant costs and unequal healthcare access.
research The Administration of Ocoxin Increases the Quality of Life of Patients with Advanced Epithelial or Metastatic Ovarian Cancer Undergoing Neoadjuvant Chemotherapy
Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.
research Efficacy of Scalp Cooling System Versus Chemical Cooling Cap in Preventing Chemotherapy-induced Alopecia in Breast Cancer (COHAIR Study): a prospective randomized trial
Both scalp cooling and chemical cooling caps effectively prevent hair loss in breast cancer patients undergoing chemotherapy.
research A Nonrandomized Clinical Trial Investigating Keratinocyte Growth Factor‐Hair Serum for the Prevention of Chemotherapy‐Induced Alopecia
Keratinocyte Growth Factor-Hair Serum may help prevent hair loss during chemotherapy, but more research is needed.
research The effect of a helmet type, home-use low-level light therapy device for chemotherapy-induced alopecia: study protocol for a randomized controlled trial
The trial is testing if a helmet that uses light can prevent hair loss during chemotherapy.
research The Dermatology Life Quality Index (DLQI ) used as the benchmark in validation of 101 quality‐of‐life instruments: A systematic review
The DLQI is a key tool for measuring quality of life in dermatology.
research Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study
Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.
research Radiotherapy-Induced Skin Fibrosis: Pathophysiology, Emerging Therapeutics, and the Role of Dermatology
Radiotherapy can cause skin fibrosis, which is often overlooked and needs better treatment and evaluation.
research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research Whole brain radiotherapy with partial hair-sparing technique-a feasibility study
Partial hair-sparing brain radiotherapy is possible and doesn't affect cancer control but still causes noticeable hair loss.
research Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.
research Cancer-Related Alopecia: From Etiologies to Global Management
The document concludes that understanding and managing hair loss in cancer patients is important, and more research is needed for better treatments.
research Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
Reporter characteristics affect detection of hair loss from cancer therapy.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research Dermoscopy of Chronic Radiation-Induced Dermatitis in Patients with Head and Neck Cancers Treated with Radiotherapy
Dermoscopy can help assess the severity of chronic radiation-induced skin damage in head and neck cancer patients.
research Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
research Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
CT-707 is effective and safe for treating certain Chinese lung cancer patients.
research 41551 Feasibility of using an integrated RCM-OCT device to identify thin Basal Cell Carcinomas amenable to ablative therapy with a Er:YAG laser: A Prospective Observational Study
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study
The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.
research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.